Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

US set to pay near­ly $2B for Pfiz­er's Covid-19 treat­ment Paxlovid in 2023

The US gov­ern­ment is tee­ing up more Pfiz­er Covid-19 an­tivi­ral pur­chas­es for next year – to the tune of $2 bil­lion.

Pfiz­er’s new agree­ment with the feds adds 3.7 mil­lion treat­ment cours­es of Paxlovid to the gov­ern­ment’s tal­ly. To date, 20 mil­lion cours­es of treat­ment have al­ready been con­tract­ed and de­liv­ered, with the newest batch set for de­liv­ery ear­ly next year.

The De­part­ment of De­fense con­tract lands just un­der $2 bil­lion for the 3.7 mil­lion cours­es. That’s in line with Pfiz­er’s orig­i­nal deal with the US gov­ern­ment for around $10.6 bil­lion for the first 20 mil­lion, which net­ted out to about $530 per treat­ment course.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.